Have any questions? 706-721-6582 or cts@augusta.edu
- BP1001-201-AML: A Phase IIa, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination with Venetoclax plus Decitabine in Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Induction Therapy
Clinical Trial
BP1001-201-AML: A Phase IIa, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination with Venetoclax plus Decitabine in Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Induction Therapy
You are invited to take part in this study because you have been diagnosed with AML (acute myeloid leukemia). One goal of this clinical research study is to learn if combining BP1001 (the study drug) with the standard-of-care drugs venetoclax and decitabine can help control the disease in patients with AML. The other goal is to learn if the BP1001 plus decitabine combination can help control the disease in patients with refractory/relapsed AML who are resistant or intolerant of venetoclax-based treatment, or not considered by their doctor as optimal candidates for venetoclax-based therapy.
Eligibility Criteria
- Male or female, aged 18 years or older Subjects with confirmed acute myeloid leukemia (AML) Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
RESEARCH. INNOVATION. DISCOVERY.